Copernicus Capital Management’s Fate Therapeutics FATE Stock Holding History

Copernicus Capital Management’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$711K	Buy	12,000 +2,000	+20%	+$157K	8.6%	6
2021 Q2	$868K	Buy	10,000 +2,000	+25%	+$161K	13.69%	2
2021 Q1	$660K	Buy	8,000 +4,760	+147%	+$456K	10.66%	3
2020 Q4	$295K	Sell	3,240 -150,057	-98%	-$9.32M	4.6%	12
2020 Q3	$6.13M	Sell	153,297 -2,208	-1%	-$77.1K	5.84%	7
2020 Q2	$5.33M	Sell	155,505 -5,454	-3%	-$163K	5.85%	9
2020 Q1	$3.58M	Sell	160,959 -1,018	-0.6%	-$25.7K	4.33%	9
2019 Q4	$3.17M	Buy	161,977 +86,977	+116%	+$1.38M	4.16%	10
2019 Q3	$1.17M	Buy	+75,000	New	+$1.44M	1.08%	16

Other funds holding FATE

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Copernicus Capital Management's FATE Position: Q3 2021 in Review

Copernicus Capital Management increased its Fate Therapeutics (FATE) stake by 20% in Q3 2021, buying an estimated $157K and bringing the position to 12,000 shares worth $711K. The position accounts for 8.6% of the portfolio, ranked #6.

Copernicus Capital Management first reported a position in FATE in Q3 2019 and has held it in 9 quarters since. The position peaked at $6.13M in Q3 2020. 265 funds tracked by Wall St. Rank hold FATE as of Q3 2021.

Copernicus Capital Management held 12,000 shares of Fate Therapeutics worth $711K as of Q3 2021.
Copernicus Capital Management bought 2,000 Fate Therapeutics shares in Q3 2021, an estimated $157K.
Fate Therapeutics made up 8.6% of Copernicus Capital Management's portfolio in Q3 2021, its #6 holding.
Copernicus Capital Management first reported a position in Fate Therapeutics in Q3 2019 and has held it in 9 quarters since.
Copernicus Capital Management's Fate Therapeutics position peaked at $6.13M in Q3 2020.
265 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2021.

Based on Copernicus Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.